Loncastuximab Tesirine and Epcoritamab
Phase 2Antibody–drug conjugate
Loncastuximab Tesirine and Epcoritamab is one of 40 small molecule programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
332 competitors in Diffuse Large B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Rayos
RRoxane Laboratories
Phase 3
Vepesid
AAvyxa
Phase 3
Adriamycin
GGynecologic Oncology Group
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Decadron
AAspen Global Incorporated
Phase 3
Leukine
SanofiPhase 3
Medrol
PfizerPhase 3
Brukinsa
BBeOne Medicines
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Antibody–drug conjugate[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversität Münster